Back to RHHBY
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
4
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
4 competitors in Metastatic Colorectal Cancer
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMAPending
Kyomarc
Treatment of breast cancer, non-small cell lung cancer, renal cell cancer, advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, platinum-sensitive epithelial ovarian, fallopian tube or primary
View on EMAEMAPending
Orblid
Treatment of adult patients with hereditary haemorrhagic telangiectasia
Orphan
View on EMAEMA5/27/2024
Lytenava
Lytenava is indicated in adults for treatment of neovascular (wet) age-related macular degeneration (nAMD).
View on EMADrug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts